New study investigates hidden heart risks in cystic fibrosis patients on modern drugs

NCT ID NCT07692594

First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This study looks at whether people with cystic fibrosis (CF) who take newer modulator drugs are developing heart disease. Researchers will use ultrasound to measure blood vessel and heart health, then repeat the tests a year later to see how things change. They will also check if standard heart-risk prediction tools work for people with CF. The goal is to find who is at highest risk so that future studies can test early prevention.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If successful, this research could help identify which people with cystic fibrosis are at highest risk for heart disease, paving the way for early prevention strategies.
What could go wrong
This is a small observational study (32 participants) that measures changes over one year. It may not capture long-term risks or apply to all people with CF.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR (CV) RISK are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Liverpool Heart and Chest Hospital

    Liverpool, L14 3PE, United Kingdom

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.